Why Bristol Myers Squibb Stock Topped the Market Today

Core Insights - Bristol Myers Squibb's stock rose over 3% following a positive quarterly and annual earnings report, contrasting with a more than 1% decline in the S&P 500 index [1] Financial Performance - In Q4 2025, Bristol Myers reported a 1% year-over-year revenue growth to $12.5 billion, driven by a 15% increase in its "growth portfolio," which generated $7.4 billion [2] - The company's net income, however, fell to $2.6 billion ($1.26 per share) from $3.4 billion in the previous year [3] - Analysts had anticipated a more significant decline in net income, projecting only $1.12 per share for non-GAAP (adjusted) net income, while Bristol Myers exceeded revenue expectations of over $12.2 billion [4] Future Outlook - For full-year 2026, management provided guidance of $46 billion to $47.5 billion in revenue and adjusted earnings of $6.05 to $6.35 per share, surpassing consensus analyst estimates of $44.2 billion for revenue and $6.02 per share for adjusted net income [5] - Despite the positive outlook, there are concerns regarding the legacy portfolio, which experienced a 16% revenue decline during the period [6]